Worsening of Parkinson's disease by citalopram

Parkinsonism and Related Disorders

Volumn 6, Issue 2, 2000, Pages 111-113

  Linazasoro, G ^a  

^a HOSPITAL QUIRÓN   (Spain)

Author keywords

Citalopram; Depression; Parkinson's disease; Serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

AFFECTIVE NEUROSIS; AGED; ARTICLE; CASE REPORT; DEPRESSION; FEMALE; HUMAN; MOTOR PERFORMANCE; NEUROTOXICITY; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM;

EID: 0033999559     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1353-8020(99)00050-4     Document Type: Article

References (17)

1. Martí Massó J.F., Carrera N., Urtasun M. Drug-induced parkinsonism: a growing list. Mov Disord. 8:1993;125.
2. Karasu T.B., Docherty J.P., Geleberg A. Practice guidelines for major depressive disorder in adults. Am J Psychiatry. 150:1993;1-26.
3. Cummings J.L. Depression and Parkinson's disease: a review. Am J Psychiatry. 149:1992;443-454.
4. Jansen Steur E.N.H. Increase of Parkinson disability after fluoxetine medication. Neurology. 43:1993;211-213.
5. Coulter D.M., Pillans P.I. Fluoxetine and extrapyramidal side effects. Am J Psychiatry. 152:1995;122-125.
6. Wils V. Extrapyramidal symptoms in a patient treated with fluvoxamine. J Neurol Neurosurg Psychiatry. 55:1992;330.
7. Shihabuddin L., Rapport D. Sertraline and extrapyramidal side effects. Am J Psychiatry. 151:1994;288.
8. Jiménez F.J., Tejeiro J., Martínez G., et al. Parkinsonism exacerbated by paroxetine. Neurology. 44:1994;2406.
9. Montastruc J.L., Fabre N., Blin O., et al. Does fluoxetine aggravate Parkinson's disease. A pilot prospective study. Mov Disord. 10:1995;355-357.
10. Richard I.H., Maughn A., Kurlan R. Do serotonin reuptake inhibitor antidepressants worsen Parkinson's disease? A retrospective case series. Mov Disord. 14:1999;155-157.
11. Milne J.R., Goa K.L. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs. 41:1991;450-477.
12. Korsgaard S., Noring U., Povlsen U.J., Gerlach J. Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 9:(Suppl. 9):1986;52-57.
13. Meltzer H.Y., Young M., Metz J., et al. Extrapyramidal side effects and increased serum prolactine following fluoxetine, a new antidepressant. J Neural Transm. 45:1979;165-175.
14. Gómez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP treated monkeys. Clin Neuropharmacol. 16:1993;418-427.
15. Durif F., Vidailhet M., Bonnet M., et al. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology. 45:1995;1855-1858.
16. Lamarre Y. Central mechanisms of experimental tremor and their clinical relevance. Findley L.J., Koller W.C. Handbook of tremor disorders. 1995;103-118 Marcel Dekker, New York.
17. Richard I.H., Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Neurology. 49:1997;1168-1170.